Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 9:13:1759720X211025894.
doi: 10.1177/1759720X211025894. eCollection 2021.

Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system

Elsa How Shing Koy  1 , Pierre Labauge  2 , Athan Baillet  3 , Clément Prati  4 , Hubert Marotte  1 , Yves-Marie Pers  5
Affiliations
Review

Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system

Elsa How Shing Koy et al. Ther Adv Musculoskelet Dis. .

Abstract

Tumor necrosis factor alpha (TNF-α) and interleukin-17 (IL-17) are two pro-inflammatory cytokines involved in the pathophysiology of spondyloarthritis (SpA). Therapies targeting TNF-α or IL-17 are used as a second line among SpA patients failing non-steroidal anti-inflammatory drugs. The choice of such treatment has to take into account the patient's comorbidities. Neurologic diseases are common and their association with SpA deserves to be studied. Therefore, the role of TNF-α and IL-17 cytokines is worth investigating in these neuropsychiatric diseases. This review aimed to explore the role of TNF-α and IL-17 in the pathogenesis of uveitis, multiple sclerosis, neuromyelitis optica, Alzheimer's disease, Parkinson's disease and depression. This update is critical to guide the therapeutic management of these co-morbidities in SpA patients.

Keywords: Alzheimer’s disease; IL-17; Parkinson’s disease; central nervous system; cytokines; depression; multiple sclerosis; neuromyelitis optica; spondyloarthritis; tumor necrosis factor alpha; uveitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: E. How Shing Koy has received honoraria from Novartis; P. Labauge has no disclosures; A. Baillet has received consultancy fees, and/or honoraria from Abbvie, Novartis, Medac, Pfizer, Galapagos, UCB; C. Prati has received consultancy fees, and/or honoraria, and/or grants from Novartis, Lilly, Abbvie, UCB, Fresenius; H. Marotte has received consultancy fees, and/or honoraria from Abbvie, Biogen, BMS, Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi, UCB; Y-M. Pers has received consultancy fees, and/or honoraria from Novartis, Pfizer.

References

    1. Moltó A, Etcheto A, van der Heijde D, et al.. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 2016; 75: 1016–1023. - PubMed
    1. Zhao SS, Robertson S, Reich T, et al.. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology (Oxford) 2020; 59(Suppl. 4): iv47–iv57. - PMC - PubMed
    1. Kotsis K, Voulgari PV, Drosos AA, et al.. Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 857–872. - PubMed
    1. Baysal O, Durmuş B, Ersoy Y, et al.. Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. Rheumatol Int 2011; 31: 795–800. - PubMed
    1. Batmaz İ, Sarıyıldız MA, Dilek B, et al.. Sleep quality and associated factors in ankylosing spondylitis: relationship with disease parameters, psychological status and quality of life. Rheumatol Int 2013; 33: 1039–1045. - PubMed

LinkOut - more resources